RECOMBINANT EPHB4-HSA FUSION PROTEIN Uses, Dosage, Side Effects and more
RECOMBINANT EPHB4-HSA FUSION PROTEIN is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).
| Attribute | Details |
|---|---|
| Trade Name | RECOMBINANT EPHB4-HSA FUSION PROTEIN |
| Generic | SEphB4-HSA |
| SEphB4-HSA Other Names | RECOMBINANT EPHB4-HSA FUSION PROTEIN |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
